Shares of Morepen Laboratories Ltd ended at ₹44.10, up by ₹0.36, or 0.82%, on the BSE.
1 Min Read
Pharmaceutical firm, Morepen Laboratories Ltd, on Tuesday (May 26) reported a 22.5% year-on-year decline in net profit at ₹15.7 crore for the fourth quarter, compared with ₹20.3 crore in the same period last year.
Revenue rose 4% year-on-year to ₹484.7 crore from ₹465.9 crore, while EBITDA declined 42.2% to ₹24.4 crore from ₹42.2 crore. EBITDA margin stood at 5%, down from 9.1% in the corresponding quarter last year.
Also Read: Morepen shares surge 15% on ₹825 crore multi-year global CDMO deal
The company’s board has recommended a final dividend of ₹0.20 per equity share of face value ₹2 each for the financial year ended March 31, 2026. The dividend is subject to approval of shareholders at the ensuing Annual General Meeting.Shares of Morepen Laboratories Ltd ended at ₹44.10, up by ₹0.36, or 0.82%, on the BSE.
(Edited by : Jomy Jos Pullokaran)
First Published: May 26, 2026 6:14 PM IS
